Full-Time

Value Director

Access & Pricing Rare Tumors, Tgct

SpringWorks Therapeutics

SpringWorks Therapeutics

201-500 employees

Clinical-stage precision medicines for cancer

Compensation Overview

$167k - $270k/yr

+ Bonus

Boston, MA, USA

Hybrid

Hybrid role; three days on-site per week at Seaport office (Boston, MA).

Bachelor's, MBA

Category
Medical, Clinical & Veterinary (1)
Required Skills
Public Policy

Get referred to SpringWorks Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor's degree (business or related disciplines)
  • MBA or other advanced degree preferred
  • 9+ years of pharmaceutical and/or biotech experience required in rare disease or Oncology
  • 5+ years in internal Market access role
  • Internal rare disease/oncology launch experience required (strategic, operational and tactical)
  • Inline rare disease/oncology product market access and cross-functional brand team experience required
  • Value/payer marketing and customer insights generation experience required
  • Experience in patient administered products (Part D, oral)
  • Experience working a collaborative, dynamic, accountable environment
  • Expert in US market access environment with knowledge of recent policy changes, external product launches and current dynamics in Rare & Oncology
  • Ability to travel to market access internal and external customer-facing meetings 30-40%
  • Strong communication both written and verbal
  • Ability to influence up and across to achieve strategic objectives, gain alignment and secure resources
Responsibilities
  • Act as the product-specific market access expert and central hub for all access-related topics, serving as the primary point of contact for cross-functional teams and informing the broader U.S. Market Access organization on product-specific developments, strategies, and insights
  • Leads the development of Market Access strategies and evidence-based payor value proposition; manages the execution of brand aligned Market Access tactical plans that influence coverage decisions and remove patient access hurdles
  • Leads strategic and tactical development and pull through of various field-based resources to support field facing teams including Strategic Enterprise Account Directors (SEADs), Field Access Managers (FAMs), and Sales teams
  • Shapes the development of pricing and contracting strategies, ensuring market competitiveness, payor acceptance and coverage policies that enable patient access
  • Manage Pricing and Government Pricing annual lifecycle, including both strategic and operational activities to maintain compliance with regulations
  • Continuously evaluates changing market and competitive dynamics to inform short and long-term strategies including but not limited to formulary positioning, contracting, pricing, real-world evidence generation and public policy
  • Leads the management of key strategic partner relationships to ensure execution of the strategic vision and tactical goals as well as the timely completion of projects within budget
  • Monitor evolving reimbursement and policy landscape and integrate insights into access strategy
  • Measure and report impact of targeted launch / access tactical plan investments
Desired Qualifications
  • Field and/or field payer experience preferred
  • New Product Pricing experience preferred
  • Understanding of Oncology value frameworks, HeOR, pricing, policy and patient advocacy preferred
  • Collaborative and curious, with innovative drive and continuous improvement mindset
  • Inclusive, humble, people-first leadership style with demonstrated examples of successful collaboration and engagement in a fast-moving environment
  • MBA or other advanced degree preferred
SpringWorks Therapeutics

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Get referred to SpringWorks Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck KGaA expects the SpringWorks deal to boost earnings per share by 2027.
  • European approval for mirdametinib broadens reimbursement and physician adoption across major EU markets.
  • Nirogacestat's long-term DeFi data in August 2025 strengthened durability and commercial credibility.

What critics are saying

  • SpringWorks lost independence on July 1, 2025; Merck KGaA now owns every asset.
  • Revenue depends heavily on nirogacestat and mirdametinib; a safety issue would crush the franchise.
  • Pimicotinib and other pipeline bets face crowded rare-oncology competition and execution delays through 2027.

What makes SpringWorks Therapeutics unique

  • Nirogacestat became the first FDA-approved desmoid tumor therapy in November 2023.
  • Mirdametinib won EU conditional approval on July 18, 2025, spanning adults and children.
  • SpringWorks built rare-tumor expertise before Merck KGaA closed the acquisition on July 1, 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Professional Development Budget

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

4%

2 year growth

4%
AD HOC NEWS
May 21st, 2026
SpringWorks Therapeutics agrees to cash merger with $3.52B market cap desmoid tumor franchise

SpringWorks Therapeutics has completed a cash merger, according to a Robinhood corporate actions update from May 2026. The Nasdaq-listed biotech, which traded at $46.99 with a market capitalisation of approximately $3.52 billion as of mid-May, focuses on developing targeted therapies for rare diseases and oncology. The company's lead asset is nirogacestat, a gamma-secretase inhibitor for desmoid tumours, addressing significant unmet medical needs in this rare soft-tissue condition. SpringWorks also develops mirdametinib, a MEK inhibitor targeting neurofibromatosis type 1 plexiform neurofibromas. As a clinical-stage company, SpringWorks currently reports negative earnings, reflecting ongoing development costs typical of pre-commercial biotechnology firms. The company operates within the US-centred biotech ecosystem, with most clinical trials and regulatory interactions based in the United States.

AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.

MedCity News
Apr 28th, 2025
Merck KGaA's Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

When SpringWorks went public in 2019, the biotech priced its shares at $18 each.